UroGen Pharma Ltd

NASDAQ:URGN  
18.16
+0.12 (+0.66%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)408.96M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9 Million
Adjusted EPS-$1.31
See more estimates
10-Day MA$19.04
50-Day MA$19.28
200-Day MA$21.08
See more pivots

UroGen Pharma Ltd Stock, NASDAQ:URGN

400 Alexander Park Drive, 4th floor, Princeton, New Jersey 08540
Israel
Phone: +1.646.768.9780
Number of Employees: 187

Description

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.